Analyst Group

Equity Research Report on Circio - Cross-Tissue Validation Sets the Stage for a Pivotal 2026

Källa: MFN
Positiv

Sammanfattning

Circio Holding har genomfört en fundamental transformation under H1-26 med nya in vivo-data som visar signifikant förbättrad genuttryck i öga och hjärta. Detta har lett till starkt externt engagemang, inklusive ett stort läkemedelsbolags studie, partnerskap och en privat placering om 250 MNOK som förlänger finansiell räckvidd till 2030.

Analys

Bolaget visar lovande resultat med sin circVec-teknologi, med upp till 50x förbättrat genuttryck i ögat och 40x i hjärtat jämfört med konventionell mRNA-baserad AAV. Detta har lett till ett flertal positiva utvecklingar: en finansierad genomförbarhetsstudie inom CNS med ett stort läkemedelsbolag, presentation vid ASGCT 2026, leveranspartnerskap med Acuitas Therapeutics och United Immunity, samt en privat placering om 250 MNOK som säkrar finansiering till 2030. Dessa framsteg positionerar Circio väl för kliniska kandidatval och licensdiskussioner.

Nyckeltal

Förbättrat genuttryck (öga)
~50x
Förbättrat genuttryck (hjärta)
~40x
Privat placering
NOK 250m
Finansiell räckvidd
Till 2030
Härlett nuvärde per aktie (Base scenario)
NOK 5.9 (2.0)

Insikter

  • • De nya data indikerar en robust validering av circVec-teknologin över olika vävnader.
  • • Den privata placeringen om 250 MNOK ger en stark finansiell buffert och förlänger runway avsevärt.
  • • Det härledda nuvärdet per aktie på 5.9 (2.0) indikerar en betydande uppsida enligt analyshuset.

Circio Holding (”Circio” or ”the Company”) has undergone a fundamental transformation during H1-26. New in vivo data demonstrate up to ~50x enhanced circVec-AAV gene expression in eye and reproduced ~40x enhancement in heart versus conventional mRNA-based AAV, establishing robust cross-tissue validation with low off-target liver signal. The data has attracted strong external engagement, including a fully funded big pharma feasibility study in CNS, an oral presentation at ASGCT 2026, delivery partnerships with Acuitas Therapeutics and United Immunity in in vivo cell therapy, and a NOK 250m private placement extending the financial runway into 2030. Circio is positioned to advance circVec toward clinical candidate selection and licensing discussions from a position that few preclinical-stage companies can match. Based on a platform-focused rNPV framework, we derive a present value of NOK 5.9 (2.0) per share in a Base scenario.

Circio Holding (”Circio” or ”the Company”) has undergone a fundamental transformation during H1-26. New in vivo data demonstrate up to ~50x enhanced circVec-AAV gene expression in eye and reproduced ~40x enhancement in heart versus conventional mRNA-based AAV, establishing robust cross-tissue validation with low off-target liver signal. The data has attracted strong external engagement, including a fully funded big pharma feasibility study in CNS, an oral presentation at ASGCT 2026, delivery partnerships with Acuitas Therapeutics and United Immunity in in vivo cell therapy, and a NOK 250m private placement extending the financial runway into 2030. Circio is positioned to advance circVec toward clinical candidate selection and licensing discussions from a position that few preclinical-stage companies can match. Based on a platform-focused rNPV framework, we derive a present value of NOK 5.9 (2.0) per share in a Base scenario.

Read the equity research report here

About Analyst Group: One of Sweden's leading analysis houses with a focus on small and medium-sized listed companies.Read more about Analyst GroupThis is a press release from Analyst Group regarding the publication of an equity research report on Circio Holding. Readers may assume that Analyst Group has received compensation for making the equity research report. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation, or anything else that could be considered a subjective assessment.